Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management
Aim The study aimed to investigate the clinical features, incidence, pathogenesis, and management of liver abscess after drug‐eluting bead transarterial chemoembolization (DEB‐TACE) for primary and metastatic hepatic malignant tumors. Methods From June 2019 to June 2021, patients with liver abscess...
Gespeichert in:
Veröffentlicht in: | Hepatology research 2024-04, Vol.54 (4), p.358-367 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 367 |
---|---|
container_issue | 4 |
container_start_page | 358 |
container_title | Hepatology research |
container_volume | 54 |
creator | Wang, Li‐Jun Yin, Liang Liu, Kai‐Cai Lv, Wei‐Fu Lu, Dong |
description | Aim
The study aimed to investigate the clinical features, incidence, pathogenesis, and management of liver abscess after drug‐eluting bead transarterial chemoembolization (DEB‐TACE) for primary and metastatic hepatic malignant tumors.
Methods
From June 2019 to June 2021, patients with liver abscess after DEB‐TACE for primary and metastatic hepatic malignant tumors were reviewed and evaluated at our hospital. Demographic and clinical data, radiological findings, management approaches, and prognosis were retrospectively analyzed.
Results
In total, 419 DEB‐TACE procedures were carried out in 314 patients with primary and metastatic liver tumors at our medical center. Twelve patients were confirmed to have liver abscesses after DEB‐TACE through clinical manifestations, laboratory investigations, and imaging. In this study, the incidence of liver abscess was 3.82% per patient and 2.86% per DEB‐TACE procedure. After percutaneous drainage and anti‐inflammatory treatments, 10 patients recovered, and the remaining 2 patients died due to direct complications of liver abscess, such as sepsis and multiple organ failure. The mortality rate of liver abscesses after DEB‐TACE was 16.7% (2/12).
Conclusion
The incidence of liver abscess after DEB‐TACE is relatively high and can have serious consequences, including death. Potential risk factors could include large tumor size, history of bile duct or tumor resection, history of diabetes, small DEB size (100–300 μm). Sensitive antibiotics therapy and percutaneous abscess aspiration/drainage are effective treatments for liver abscess after DEB‐TACE. |
doi_str_mv | 10.1111/hepr.13985 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2886328739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2886328739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3165-a383fdc7464903a9e24273bb22788a79843345a715cb63f30980b54d8c74750a3</originalsourceid><addsrcrecordid>eNp9kcGK1TAUhosozji68QEk4EbEjklO2qSzk8voCBcUUXBXTtvT3gxtck1SZVz5CG58QZ_EjHd04cJskp98_8_h_EXxUPBTkc_zHe3DqYDGVLeKY2G0LDmoj7fzG0xd1qDqo-JejJecC82lulscgW6kqnh9XPzY2s8UGHaxpxgZjimrIazTz2_faV6TdRPrCAeWArqIIX9bnFm_o8XT0vnZfsVkvWOjDywPkkXPFpzt5NAlltbFh3jGNrN1ts_GkTCtgeIzltGdn8hRtFmhG7LN4UQLuXS_uDPiHOnBzX1SfHh5_n5zUW7fvHq9ebEtexB1VSIYGIdeq1o1HLAhqaSGrpNSG4O6MQpAVahF1Xc1jMAbw7tKDSZbdMURToonh9x98J9WiqldbF7EPKMjv8ZWGlODNBqajD7-B730a3B5uhY4cC2FqEymnh6oPvgYA43tPtgFw1UreHtdVntdVvu7rAw_uolcu4WGv-ifdjIgDsAXO9PVf6Lai_O37w6hvwBTZKIG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3030721158</pqid></control><display><type>article</type><title>Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management</title><source>Access via Wiley Online Library</source><creator>Wang, Li‐Jun ; Yin, Liang ; Liu, Kai‐Cai ; Lv, Wei‐Fu ; Lu, Dong</creator><creatorcontrib>Wang, Li‐Jun ; Yin, Liang ; Liu, Kai‐Cai ; Lv, Wei‐Fu ; Lu, Dong</creatorcontrib><description>Aim
The study aimed to investigate the clinical features, incidence, pathogenesis, and management of liver abscess after drug‐eluting bead transarterial chemoembolization (DEB‐TACE) for primary and metastatic hepatic malignant tumors.
Methods
From June 2019 to June 2021, patients with liver abscess after DEB‐TACE for primary and metastatic hepatic malignant tumors were reviewed and evaluated at our hospital. Demographic and clinical data, radiological findings, management approaches, and prognosis were retrospectively analyzed.
Results
In total, 419 DEB‐TACE procedures were carried out in 314 patients with primary and metastatic liver tumors at our medical center. Twelve patients were confirmed to have liver abscesses after DEB‐TACE through clinical manifestations, laboratory investigations, and imaging. In this study, the incidence of liver abscess was 3.82% per patient and 2.86% per DEB‐TACE procedure. After percutaneous drainage and anti‐inflammatory treatments, 10 patients recovered, and the remaining 2 patients died due to direct complications of liver abscess, such as sepsis and multiple organ failure. The mortality rate of liver abscesses after DEB‐TACE was 16.7% (2/12).
Conclusion
The incidence of liver abscess after DEB‐TACE is relatively high and can have serious consequences, including death. Potential risk factors could include large tumor size, history of bile duct or tumor resection, history of diabetes, small DEB size (100–300 μm). Sensitive antibiotics therapy and percutaneous abscess aspiration/drainage are effective treatments for liver abscess after DEB‐TACE.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.13985</identifier><identifier>PMID: 37924506</identifier><language>eng</language><publisher>Netherlands: Wiley Subscription Services, Inc</publisher><subject>Abscesses ; Antibiotics ; Bile ducts ; Chemoembolization ; complication ; Diabetes mellitus ; drug‐eluting bead transarterial chemoembolization (DEB‐TACE) ; hepatic malignant tumor ; Inflammation ; Liver ; liver abscess ; Metastases ; Metastasis ; Pathogenesis ; Patients ; Risk factors ; Sepsis ; Tumors ; Wound drainage</subject><ispartof>Hepatology research, 2024-04, Vol.54 (4), p.358-367</ispartof><rights>2023 Japan Society of Hepatology.</rights><rights>2024 The Japan Society of Hepatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3165-a383fdc7464903a9e24273bb22788a79843345a715cb63f30980b54d8c74750a3</cites><orcidid>0000-0001-8117-1554 ; 0000-0002-3561-7209</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhepr.13985$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhepr.13985$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37924506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Li‐Jun</creatorcontrib><creatorcontrib>Yin, Liang</creatorcontrib><creatorcontrib>Liu, Kai‐Cai</creatorcontrib><creatorcontrib>Lv, Wei‐Fu</creatorcontrib><creatorcontrib>Lu, Dong</creatorcontrib><title>Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Aim
The study aimed to investigate the clinical features, incidence, pathogenesis, and management of liver abscess after drug‐eluting bead transarterial chemoembolization (DEB‐TACE) for primary and metastatic hepatic malignant tumors.
Methods
From June 2019 to June 2021, patients with liver abscess after DEB‐TACE for primary and metastatic hepatic malignant tumors were reviewed and evaluated at our hospital. Demographic and clinical data, radiological findings, management approaches, and prognosis were retrospectively analyzed.
Results
In total, 419 DEB‐TACE procedures were carried out in 314 patients with primary and metastatic liver tumors at our medical center. Twelve patients were confirmed to have liver abscesses after DEB‐TACE through clinical manifestations, laboratory investigations, and imaging. In this study, the incidence of liver abscess was 3.82% per patient and 2.86% per DEB‐TACE procedure. After percutaneous drainage and anti‐inflammatory treatments, 10 patients recovered, and the remaining 2 patients died due to direct complications of liver abscess, such as sepsis and multiple organ failure. The mortality rate of liver abscesses after DEB‐TACE was 16.7% (2/12).
Conclusion
The incidence of liver abscess after DEB‐TACE is relatively high and can have serious consequences, including death. Potential risk factors could include large tumor size, history of bile duct or tumor resection, history of diabetes, small DEB size (100–300 μm). Sensitive antibiotics therapy and percutaneous abscess aspiration/drainage are effective treatments for liver abscess after DEB‐TACE.</description><subject>Abscesses</subject><subject>Antibiotics</subject><subject>Bile ducts</subject><subject>Chemoembolization</subject><subject>complication</subject><subject>Diabetes mellitus</subject><subject>drug‐eluting bead transarterial chemoembolization (DEB‐TACE)</subject><subject>hepatic malignant tumor</subject><subject>Inflammation</subject><subject>Liver</subject><subject>liver abscess</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Risk factors</subject><subject>Sepsis</subject><subject>Tumors</subject><subject>Wound drainage</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kcGK1TAUhosozji68QEk4EbEjklO2qSzk8voCBcUUXBXTtvT3gxtck1SZVz5CG58QZ_EjHd04cJskp98_8_h_EXxUPBTkc_zHe3DqYDGVLeKY2G0LDmoj7fzG0xd1qDqo-JejJecC82lulscgW6kqnh9XPzY2s8UGHaxpxgZjimrIazTz2_faV6TdRPrCAeWArqIIX9bnFm_o8XT0vnZfsVkvWOjDywPkkXPFpzt5NAlltbFh3jGNrN1ts_GkTCtgeIzltGdn8hRtFmhG7LN4UQLuXS_uDPiHOnBzX1SfHh5_n5zUW7fvHq9ebEtexB1VSIYGIdeq1o1HLAhqaSGrpNSG4O6MQpAVahF1Xc1jMAbw7tKDSZbdMURToonh9x98J9WiqldbF7EPKMjv8ZWGlODNBqajD7-B730a3B5uhY4cC2FqEymnh6oPvgYA43tPtgFw1UreHtdVntdVvu7rAw_uolcu4WGv-ifdjIgDsAXO9PVf6Lai_O37w6hvwBTZKIG</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Wang, Li‐Jun</creator><creator>Yin, Liang</creator><creator>Liu, Kai‐Cai</creator><creator>Lv, Wei‐Fu</creator><creator>Lu, Dong</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8117-1554</orcidid><orcidid>https://orcid.org/0000-0002-3561-7209</orcidid></search><sort><creationdate>202404</creationdate><title>Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management</title><author>Wang, Li‐Jun ; Yin, Liang ; Liu, Kai‐Cai ; Lv, Wei‐Fu ; Lu, Dong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3165-a383fdc7464903a9e24273bb22788a79843345a715cb63f30980b54d8c74750a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Abscesses</topic><topic>Antibiotics</topic><topic>Bile ducts</topic><topic>Chemoembolization</topic><topic>complication</topic><topic>Diabetes mellitus</topic><topic>drug‐eluting bead transarterial chemoembolization (DEB‐TACE)</topic><topic>hepatic malignant tumor</topic><topic>Inflammation</topic><topic>Liver</topic><topic>liver abscess</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Risk factors</topic><topic>Sepsis</topic><topic>Tumors</topic><topic>Wound drainage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Li‐Jun</creatorcontrib><creatorcontrib>Yin, Liang</creatorcontrib><creatorcontrib>Liu, Kai‐Cai</creatorcontrib><creatorcontrib>Lv, Wei‐Fu</creatorcontrib><creatorcontrib>Lu, Dong</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Li‐Jun</au><au>Yin, Liang</au><au>Liu, Kai‐Cai</au><au>Lv, Wei‐Fu</au><au>Lu, Dong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2024-04</date><risdate>2024</risdate><volume>54</volume><issue>4</issue><spage>358</spage><epage>367</epage><pages>358-367</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aim
The study aimed to investigate the clinical features, incidence, pathogenesis, and management of liver abscess after drug‐eluting bead transarterial chemoembolization (DEB‐TACE) for primary and metastatic hepatic malignant tumors.
Methods
From June 2019 to June 2021, patients with liver abscess after DEB‐TACE for primary and metastatic hepatic malignant tumors were reviewed and evaluated at our hospital. Demographic and clinical data, radiological findings, management approaches, and prognosis were retrospectively analyzed.
Results
In total, 419 DEB‐TACE procedures were carried out in 314 patients with primary and metastatic liver tumors at our medical center. Twelve patients were confirmed to have liver abscesses after DEB‐TACE through clinical manifestations, laboratory investigations, and imaging. In this study, the incidence of liver abscess was 3.82% per patient and 2.86% per DEB‐TACE procedure. After percutaneous drainage and anti‐inflammatory treatments, 10 patients recovered, and the remaining 2 patients died due to direct complications of liver abscess, such as sepsis and multiple organ failure. The mortality rate of liver abscesses after DEB‐TACE was 16.7% (2/12).
Conclusion
The incidence of liver abscess after DEB‐TACE is relatively high and can have serious consequences, including death. Potential risk factors could include large tumor size, history of bile duct or tumor resection, history of diabetes, small DEB size (100–300 μm). Sensitive antibiotics therapy and percutaneous abscess aspiration/drainage are effective treatments for liver abscess after DEB‐TACE.</abstract><cop>Netherlands</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37924506</pmid><doi>10.1111/hepr.13985</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-8117-1554</orcidid><orcidid>https://orcid.org/0000-0002-3561-7209</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1386-6346 |
ispartof | Hepatology research, 2024-04, Vol.54 (4), p.358-367 |
issn | 1386-6346 1872-034X |
language | eng |
recordid | cdi_proquest_miscellaneous_2886328739 |
source | Access via Wiley Online Library |
subjects | Abscesses Antibiotics Bile ducts Chemoembolization complication Diabetes mellitus drug‐eluting bead transarterial chemoembolization (DEB‐TACE) hepatic malignant tumor Inflammation Liver liver abscess Metastases Metastasis Pathogenesis Patients Risk factors Sepsis Tumors Wound drainage |
title | Liver abscess after drug‐eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T23%3A56%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver%20abscess%20after%20drug%E2%80%90eluting%20bead%20transarterial%20chemoembolization%20for%20hepatic%20malignant%20tumors:%20Clinical%20features,%20pathogenesis,%20and%20management&rft.jtitle=Hepatology%20research&rft.au=Wang,%20Li%E2%80%90Jun&rft.date=2024-04&rft.volume=54&rft.issue=4&rft.spage=358&rft.epage=367&rft.pages=358-367&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.13985&rft_dat=%3Cproquest_cross%3E2886328739%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3030721158&rft_id=info:pmid/37924506&rfr_iscdi=true |